J&J beats quarterly sales and profit estimates on cancer drug sales
NEW BRUNSWICK, New Jersey: Johnson & Johnson exceeded Wall Street expectations for fourth-quarter revenue and profit, with robust sales of cancer treatments leading the charge.
The company recently announced its US$14.6 billion acquisition of Intra-Cellular to strengthen its psychiatric drug portfolio. This move is expected to impact annual earnings by 30-35 cents per share this year.
For 2025, J&J forec